查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1492544

Dravet 症候群市場：按產品、癲癇類型、嚴重程度、按最終用戶 - 2024-2030 年全球預測

Dravet Syndrome Market by Offering (Diagnosis & Testing Solutions, Dietary Therapies, Medications), Seizure Type (Atonic Seizures, Myoclonic Seizures, Partial seizures), Severity, End-Use - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 195 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

Dravet 症候群市場規模預計 2023 年為 6.7647 億美元，2024 年達到 7.3404 億美元，預計 2030 年將達到 12.1321 億美元，複合年成長率為 8.70%。

Dravet 症候群被認為是一種嚴重的癲癇症，發生在兒童出生後的第一年，其特徵是頻繁且長時間的癲癇發作，通常由高熱和發燒引發。這種疾病主要是由影響 SCN1A 基因的基因突變引起的，該基因在腦細胞功能中發揮重要作用。研究_KEYWORD 理解和治療選擇的擴展歸因於基因治療的技術進步、大麻素治療研究的增加以及對個人化醫療的重視。然而，治療這種症候群面臨著巨大的挑戰，包括治療費用高昂、某些地區獲得有效治療方法的機會有限以及普通人群對該疾病的認知較低。然而，特異性針對潛在遺傳異常的更複雜的基因療法的開拓代表了市場成長的機會。此外，正在進行的新藥物治療方法研究有望透過提供更有效的症狀管理和更少的副作用來改善受影響個體的生活品質。

主要市場統計
基準年[2023] 67647萬美元
預測年份 [2024] 73404萬美元
預測年份 [2030] 12.1321億美元
複合年成長率（%） 8.70%

區域洞察

由於對 Dravet 症候群的認知相對較高、診斷率較高以及先進的醫療服務，美洲的 Dravet 症候群市場呈現出發達的態勢，特別是在美國和加拿大。在強大的醫療資金和保險系統的支持下，該地區正在引入新的治療方法和臨床試驗。看看EMEA（歐洲、中東和非洲），西歐在先進的醫療設施和患者支援計劃方面與美洲相似，但東歐和中東和非洲在經濟狀況和醫療保健發展方面也存在差異。 。就亞太地區而言，市場動態有顯著差異。儘管日本和澳洲等國家表現出與西方國家相當的高水準意識和醫療保健支持，但亞洲低度開發地區對基本醫療基礎設施和專業醫療保健服務的需求仍然存在大量未滿足的需求。這些地區的整體市場成長是由 Dravet 症候群盛行率上升、診斷機制的進步以及政府和非政府對研究和治療支持的增加等因素所推動的。

FPNV定位矩陣

FPNV 定位矩陣對於評估 Dravet 症候群市場中供應商的定位至關重要。此矩陣提供了對供應商的全面評估，並檢查了與商務策略和產品滿意度相關的關鍵指標。這種詳細的評估使用戶能夠根據自己的要求做出明智的決定。根據評估結果，供應商被分為代表其成功程度的四個像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市場佔有率分析

市場佔有率分析是一種綜合工具，可對 Dravet 症候群市場中供應商的當前狀態進行深入而詳細的評估。對供應商貢獻的徹底比較和分析可以更深入地了解每個供應商的績效以及他們在爭奪市場佔有率時面臨的挑戰。這些貢獻包括整體收益、客戶群和其他重要指標。此外，該分析還提供了對該行業競爭力的寶貴見解，包括在研究基準年期間觀察到的累積、分散主導地位和合併特徵等因素。有了這些詳細資訊，供應商可以做出更明智的決策並製定有效的策略，以在市場競爭中保持領先地位。

策略分析與建議

策略分析對於尋求在全球市場站穩腳跟的組織至關重要。對 Dravet 綜合症市場當前地位的全面評估使公司能夠做出符合其長期願望的明智決策。此關鍵評估涉及對組織的資源、能力和整體績效進行徹底分析，以確定核心優勢和需要改進的領域。

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 增加旨在了解遺傳疾病的研究和開發活動
      • 人們對罕見疾病的認知不斷增強
      • 支持 Dravet 症候群治療方法和藥物開發的法規環境
    • 抑制因素
      • Dravet 症候群相關治療費用上漲
    • 機會
      • Dravet症候群治療方法與藥物基因治療的進展
      • 增加對罕見疾病研究的資助
    • 任務
      • 診斷挑戰會導致誤診和正確診斷的延誤。
  • 市場區隔分析
    • 我們提供的服務：普及藥物來控制癲癇發作並減少癲癇發作的頻率。
    • 最終用途：醫院在急診和管理以及提供專業設備方面的關鍵作用
  • 市場擾動分析
  • 波特五力分析
  • 價值鍊和關鍵路徑分析
  • 價格分析
  • 技術分析
  • 專利分析
  • 貿易分析
  • 法規結構分析

第 6 章 Dravet 症候群市場：透過提供

  • 診斷和測試解決方案
  • 飲食療法
  • 藥品

第 7 章 Dravet 症候群市場（依癲癇發作類型）

  • 失張力發作
  • 肌陣攣發作
  • 局部性發作
  • 光敏性癲癇發作
  • 強直陣攣發作

第 8 章 Dravet 症候群市場（依嚴重程度）

  • 溫和的
  • 適度
  • 嚴重

第 9 章 Dravet 症候群市場：依最終用途

  • 居家護理
  • 醫院
  • 專科診所

第10章美洲Dravet症候群市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第11章 亞太地區Dravet症候群市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第12章歐洲、中東和非洲Dravet症候群市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第13章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣，2023
  • 競爭情境分析
    • STK-001在管理上的突破性功效：臨床試驗綜合分析及未來展望
    • FDA 和 TGA核准將 Encoded Therapeutics 的基因療法 ETX101 納入 Dravet 症候群的臨床試驗
    • 腸腦軸研究取得突破：Bloom Science 的 BL-001 在治療 Dravet 症候群和 ALS 方面顯示出有希望的 1 期試驗結果
  • 戰略分析和建議

第14章競爭產品組合

  • 主要企業簡介
  • 主要產品系列
Product Code: MRR-4D00F1312C81

[195 Pages Report] The Dravet Syndrome Market size was estimated at USD 676.47 million in 2023 and expected to reach USD 734.04 million in 2024, at a CAGR 8.70% to reach USD 1,213.21 million by 2030.

Dravet Syndrome is considered a severe form of epilepsy that emerges in the first year of a child's life and is characterized by frequent, prolonged seizures often triggered by high body temperatures or fever. This condition typically arises due to genetic mutations, primarily affecting the SCN1A gene, which plays a crucial role in brain cell functioning. The expansion in the understanding and treatment options for Dravet Syndrome can be attributed to technological advances in gene therapy, increased research into cannabinoid treatments, and a greater emphasis on personalized medicine. However, managing this syndrome presents significant challenges, such as high treatment costs, limited access to effective treatments in some regions, and a lack of awareness about the disorder among the general population. Nevertheless, the development of more sophisticated gene therapies that specifically target the underlying genetic abnormalities presents an opportunistic view for market growth. Furthermore, ongoing research into new pharmacological treatments promises to improve the quality of life for those affected by offering more effective management of symptoms with fewer side effects.

KEY MARKET STATISTICS
Base Year [2023] USD 676.47 million
Estimated Year [2024] USD 734.04 million
Forecast Year [2030] USD 1,213.21 million
CAGR (%) 8.70%

Regional Insights

The Dravet syndrome market in the Americas shows a developed landscape, particularly in the United States and Canada, with relatively high awareness of Dravet Syndrome and better diagnosis rates and access to advanced healthcare services. This region often leads to the adoption of new therapies and clinical trials, which are supported by robust healthcare funding and insurance schemes. Moving to EMEA, Western Europe mirrors the Americas in terms of advanced medical facilities and patient support programs, yet Eastern Europe, the Middle East, and Africa may exhibit varied access levels due, in part, to disparate economic conditions and healthcare development. As for the Asia Pacific, this region experiences a wide disparity in market dynamics. Countries including Japan and Australia show high awareness and good healthcare support, comparable to Western nations, whereas in less developed parts of Asia, there remains a significant unmet need for basic medical infrastructure and specialist healthcare services. The overall market growth in these regions is driven by factors including the elevating incidence of Dravet Syndrome, progressively better diagnostic mechanisms, and increasing government and non-government support for research and treatment.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Dravet Syndrome Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Increase in research and development activities aimed at understanding genetic disorders
      • Rising awareness of rare diseases
      • Supportive regulatory environments for developments in Dravet syndrome therapies and medications
    • Market Restraints
      • High cost of treatment associated with Dravet syndrome
    • Market Opportunities
      • Advancements in genetic therapy for Dravet syndrome therapies and medications
      • Increased funding for rare disease research
    • Market Challenges
      • Diagnostic challenges leading to misdiagnosis or delays in correct diagnosis
  • Market Segmentation Analysis
    • Offering: Proliferation of medications to manage & reduce the frequency of seizures
    • End-Use: Pivotal role of hospitals in treating and managing acute episodes and providing access to specialized equipment
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Dravet Syndrome Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Dravet Syndrome Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Breakthrough Efficacy of STK-001 in Dravet Syndrome Management: A Comprehensive Analysis of Clinical Trials and Future Prospects

In a series of pivotal clinical trials, including the phase 1/2a MONARCH and ADMIRAL, alongside their respective open-label extensions SWALLOWTAIL and LONGWING, STK-001, an investigational antisense oligonucleotide developed by Stoke Therapeutics, has demonstrated significant efficacy in reducing convulsive seizure frequencies among patients with Dravet syndrome. These treatments are typically multi-drug regimens, highlighting STK-001's robust mechanism that potentially modifies disease pathology rather than merely alleviating symptoms. Encoded Therapeutics' ETX101, representing another advanced gene therapy solution for Dravet syndrome, further reinforces the evolving therapeutic landscape, carving paths to potentially transformative care paradigms. [Published On: 2024-04-11]

FDA and TGA Approval Ushers Encoded Therapeutics' Gene Therapy ETX101 into Clinical Trials for Dravet Syndrome

Encoded Therapeutics has received FDA clearance and TGA approval for its Investigational New Drug application for ETX101, an AAV9-mediated gene regulation therapy aimed at treating Dravet syndrome by upregulating the SCN1A gene in GABAergic inhibitory interneurons. This is seen as a potential breakthrough in addressing the root causes of the disease, characterized by severe seizures. ETX101 will now enter the ENDEAVOR and WAYFINDER clinical trials under the international POLARIS program. These Phase I/II trials, scheduled to kick off in the first half of this year in the US and Australia, respectively, will assess the efficacy and safety of ETX101 in different pediatric age groups. [Published On: 2024-02-07]

Breakthrough in Gut-Brain Axis Research: Bloom Science's BL-001 Shows Promising Phase 1 Results for Treatment of Dravet Syndrome and ALS

Bloom Science, Inc. has announced encouraging outcomes from a Phase 1 clinical trial evaluating BL-001, a novel orally-administered Live Biotherapeutic Product (LBP). This clinical trial tested BL-001's safety, tolerability, and biological activity in healthy volunteers, revealing a positive safety profile with no Serious Adverse Events reported. Bloom Science is poised to commence Phase 2 trials in 2024 for both Dravet syndrome and amyotrophic lateral sclerosis (ALS), aiming to fulfill a critical need for new, effective therapies in these conditions. [Published On: 2023-08-17]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Dravet Syndrome Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Dravet Syndrome Market, highlighting leading vendors and their innovative profiles. These include Biocodex S.A., Bloom Science, Inc., Cyberonics, Inc., Eisai Co., Ltd., Encoded Therapeutics, Epygenix Therapeutics, GW Pharmaceuticals by Jazz Pharmaceuticals plc, Insys Therapeutics, Inc., Longboard Pharmaceuticals, Inc., OPKO Health Inc., Ovid Therapeutics Inc., PTC Therapeutics, Sage Therapeutics, Stoke Therapeutics, Supernus Pharmaceuticals, Inc., Takeda Pharmaceutical Company Limited, Virpax Pharmaceuticals, Xenon Pharmaceuticals, and Zogenix Inc by UCB.

Market Segmentation & Coverage

This research report categorizes the Dravet Syndrome Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Offering
    • Diagnosis & Testing Solutions
      • Electroencephalogram
      • Genetic Testing
      • MRI & CT Scans
    • Dietary Therapies
    • Medications
      • Clobazam
      • Stiripentol
      • Valproate
  • Seizure Type
    • Atonic Seizures
    • Myoclonic Seizures
    • Partial seizures
    • Photosensitive Seizures
    • Tonic-Clonic Seizures
  • Severity
    • Mild
    • Moderate
    • Severe
  • End-Use
    • Homecare
    • Hospitals
    • Specialty Clinics
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increase in research and development activities aimed at understanding genetic disorders
      • 5.1.1.2. Rising awareness of rare diseases
      • 5.1.1.3. Supportive regulatory environments for developments in Dravet syndrome therapies and medications
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of treatment associated with Dravet syndrome
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in genetic therapy for Dravet syndrome therapies and medications
      • 5.1.3.2. Increased funding for rare disease research
    • 5.1.4. Challenges
      • 5.1.4.1. Diagnostic challenges leading to misdiagnosis or delays in correct diagnosis
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Offering: Proliferation of medications to manage & reduce the frequency of seizures
    • 5.2.2. End-Use: Pivotal role of hospitals in treating and managing acute episodes and providing access to specialized equipment
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Dravet Syndrome Market, by Offering

  • 6.1. Introduction
  • 6.2. Diagnosis & Testing Solutions
  • 6.3. Dietary Therapies
  • 6.4. Medications

7. Dravet Syndrome Market, by Seizure Type

  • 7.1. Introduction
  • 7.2. Atonic Seizures
  • 7.3. Myoclonic Seizures
  • 7.4. Partial seizures
  • 7.5. Photosensitive Seizures
  • 7.6. Tonic-Clonic Seizures

8. Dravet Syndrome Market, by Severity

  • 8.1. Introduction
  • 8.2. Mild
  • 8.3. Moderate
  • 8.4. Severe

9. Dravet Syndrome Market, by End-Use

  • 9.1. Introduction
  • 9.2. Homecare
  • 9.3. Hospitals
  • 9.4. Specialty Clinics

10. Americas Dravet Syndrome Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Dravet Syndrome Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Dravet Syndrome Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Breakthrough Efficacy of STK-001 in Dravet Syndrome Management: A Comprehensive Analysis of Clinical Trials and Future Prospects
    • 13.3.2. FDA and TGA Approval Ushers Encoded Therapeutics' Gene Therapy ETX101 into Clinical Trials for Dravet Syndrome
    • 13.3.3. Breakthrough in Gut-Brain Axis Research: Bloom Science's BL-001 Shows Promising Phase 1 Results for Treatment of Dravet Syndrome and ALS
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. DRAVET SYNDROME MARKET RESEARCH PROCESS
  • FIGURE 2. DRAVET SYNDROME MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL DRAVET SYNDROME MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL DRAVET SYNDROME MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL DRAVET SYNDROME MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. DRAVET SYNDROME MARKET DYNAMICS
  • FIGURE 7. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END-USE, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END-USE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. DRAVET SYNDROME MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. DRAVET SYNDROME MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. DRAVET SYNDROME MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL DRAVET SYNDROME MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL DRAVET SYNDROME MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL DRAVET SYNDROME MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL DRAVET SYNDROME MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ELECTROENCEPHALOGRAM, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ELECTROENCEPHALOGRAM, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GENETIC TESTING, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL DRAVET SYNDROME MARKET SIZE, BY GENETIC TESTING, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MRI & CT SCANS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MRI & CT SCANS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIETARY THERAPIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL DRAVET SYNDROME MARKET SIZE, BY DIETARY THERAPIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CLOBAZAM, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL DRAVET SYNDROME MARKET SIZE, BY CLOBAZAM, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL DRAVET SYNDROME MARKET SIZE, BY STIRIPENTOL, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL DRAVET SYNDROME MARKET SIZE, BY STIRIPENTOL, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL DRAVET SYNDROME MARKET SIZE, BY VALPROATE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL DRAVET SYNDROME MARKET SIZE, BY VALPROATE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ATONIC SEIZURES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL DRAVET SYNDROME MARKET SIZE, BY ATONIC SEIZURES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MYOCLONIC SEIZURES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MYOCLONIC SEIZURES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL DRAVET SYNDROME MARKET SIZE, BY PARTIAL SEIZURES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL DRAVET SYNDROME MARKET SIZE, BY PARTIAL SEIZURES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL DRAVET SYNDROME MARKET SIZE, BY PHOTOSENSITIVE SEIZURES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL DRAVET SYNDROME MARKET SIZE, BY PHOTOSENSITIVE SEIZURES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TONIC-CLONIC SEIZURES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 42. GLOBAL DRAVET SYNDROME MARKET SIZE, BY TONIC-CLONIC SEIZURES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 43. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2023 (USD MILLION)
  • TABLE 44. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2024-2030 (USD MILLION)
  • TABLE 45. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MILD, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 46. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MILD, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 47. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MODERATE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 48. GLOBAL DRAVET SYNDROME MARKET SIZE, BY MODERATE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 49. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEVERE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 50. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SEVERE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 51. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 52. GLOBAL DRAVET SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 53. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOMECARE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 54. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOMECARE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 55. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 56. GLOBAL DRAVET SYNDROME MARKET SIZE, BY HOSPITALS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 57. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 58. GLOBAL DRAVET SYNDROME MARKET SIZE, BY SPECIALTY CLINICS, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 59. AMERICAS DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 60. AMERICAS DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 61. AMERICAS DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2023 (USD MILLION)
  • TABLE 62. AMERICAS DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2024-2030 (USD MILLION)
  • TABLE 63. AMERICAS DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 64. AMERICAS DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 65. AMERICAS DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 66. AMERICAS DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 67. AMERICAS DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2023 (USD MILLION)
  • TABLE 68. AMERICAS DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2024-2030 (USD MILLION)
  • TABLE 69. AMERICAS DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 70. AMERICAS DRAVET SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 71. AMERICAS DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 72. AMERICAS DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 73. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 74. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 75. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2023 (USD MILLION)
  • TABLE 76. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2024-2030 (USD MILLION)
  • TABLE 77. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 78. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 79. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 80. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 81. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2023 (USD MILLION)
  • TABLE 82. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2024-2030 (USD MILLION)
  • TABLE 83. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 84. ARGENTINA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 85. BRAZIL DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 86. BRAZIL DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 87. BRAZIL DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2023 (USD MILLION)
  • TABLE 88. BRAZIL DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2024-2030 (USD MILLION)
  • TABLE 89. BRAZIL DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 90. BRAZIL DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 91. BRAZIL DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 92. BRAZIL DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 93. BRAZIL DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2023 (USD MILLION)
  • TABLE 94. BRAZIL DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2024-2030 (USD MILLION)
  • TABLE 95. BRAZIL DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 96. BRAZIL DRAVET SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 97. CANADA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 98. CANADA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 99. CANADA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2023 (USD MILLION)
  • TABLE 100. CANADA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2024-2030 (USD MILLION)
  • TABLE 101. CANADA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 102. CANADA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 103. CANADA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 104. CANADA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 105. CANADA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2023 (USD MILLION)
  • TABLE 106. CANADA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2024-2030 (USD MILLION)
  • TABLE 107. CANADA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 108. CANADA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 109. MEXICO DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 110. MEXICO DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 111. MEXICO DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2023 (USD MILLION)
  • TABLE 112. MEXICO DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2024-2030 (USD MILLION)
  • TABLE 113. MEXICO DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 114. MEXICO DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 115. MEXICO DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 116. MEXICO DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 117. MEXICO DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2023 (USD MILLION)
  • TABLE 118. MEXICO DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2024-2030 (USD MILLION)
  • TABLE 119. MEXICO DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 120. MEXICO DRAVET SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 121. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 122. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 123. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2023 (USD MILLION)
  • TABLE 124. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2024-2030 (USD MILLION)
  • TABLE 125. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 126. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 127. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 128. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 129. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2023 (USD MILLION)
  • TABLE 130. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2024-2030 (USD MILLION)
  • TABLE 131. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 132. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 133. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 134. UNITED STATES DRAVET SYNDROME MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 135. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 136. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 137. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2023 (USD MILLION)
  • TABLE 138. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2024-2030 (USD MILLION)
  • TABLE 139. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 140. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 141. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 142. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 143. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2023 (USD MILLION)
  • TABLE 144. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2024-2030 (USD MILLION)
  • TABLE 145. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 146. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 147. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 148. ASIA-PACIFIC DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 149. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 150. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 151. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2023 (USD MILLION)
  • TABLE 152. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2024-2030 (USD MILLION)
  • TABLE 153. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 154. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 155. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 156. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 157. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2023 (USD MILLION)
  • TABLE 158. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2024-2030 (USD MILLION)
  • TABLE 159. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 160. AUSTRALIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 161. CHINA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 162. CHINA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 163. CHINA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2023 (USD MILLION)
  • TABLE 164. CHINA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2024-2030 (USD MILLION)
  • TABLE 165. CHINA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 166. CHINA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 167. CHINA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 168. CHINA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 169. CHINA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2023 (USD MILLION)
  • TABLE 170. CHINA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2024-2030 (USD MILLION)
  • TABLE 171. CHINA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 172. CHINA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 173. INDIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 174. INDIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 175. INDIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2023 (USD MILLION)
  • TABLE 176. INDIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2024-2030 (USD MILLION)
  • TABLE 177. INDIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 178. INDIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 179. INDIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 180. INDIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 181. INDIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2023 (USD MILLION)
  • TABLE 182. INDIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2024-2030 (USD MILLION)
  • TABLE 183. INDIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 184. INDIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 185. INDONESIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 186. INDONESIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 187. INDONESIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2023 (USD MILLION)
  • TABLE 188. INDONESIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2024-2030 (USD MILLION)
  • TABLE 189. INDONESIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 190. INDONESIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 191. INDONESIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 192. INDONESIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 193. INDONESIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2023 (USD MILLION)
  • TABLE 194. INDONESIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2024-2030 (USD MILLION)
  • TABLE 195. INDONESIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 196. INDONESIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 197. JAPAN DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 198. JAPAN DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 199. JAPAN DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2023 (USD MILLION)
  • TABLE 200. JAPAN DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2024-2030 (USD MILLION)
  • TABLE 201. JAPAN DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 202. JAPAN DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 203. JAPAN DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 204. JAPAN DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 205. JAPAN DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2023 (USD MILLION)
  • TABLE 206. JAPAN DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2024-2030 (USD MILLION)
  • TABLE 207. JAPAN DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 208. JAPAN DRAVET SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 209. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 210. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 211. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2023 (USD MILLION)
  • TABLE 212. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2024-2030 (USD MILLION)
  • TABLE 213. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 214. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 215. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 216. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 217. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2023 (USD MILLION)
  • TABLE 218. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2024-2030 (USD MILLION)
  • TABLE 219. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 220. MALAYSIA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 221. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 222. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 223. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2023 (USD MILLION)
  • TABLE 224. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2024-2030 (USD MILLION)
  • TABLE 225. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 226. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 227. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 228. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 229. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2023 (USD MILLION)
  • TABLE 230. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2024-2030 (USD MILLION)
  • TABLE 231. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 232. PHILIPPINES DRAVET SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 233. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 234. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 235. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2023 (USD MILLION)
  • TABLE 236. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2024-2030 (USD MILLION)
  • TABLE 237. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 238. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 239. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 240. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 241. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2023 (USD MILLION)
  • TABLE 242. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2024-2030 (USD MILLION)
  • TABLE 243. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 244. SINGAPORE DRAVET SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 245. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 246. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 247. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2023 (USD MILLION)
  • TABLE 248. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2024-2030 (USD MILLION)
  • TABLE 249. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 250. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 251. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 252. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 253. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2023 (USD MILLION)
  • TABLE 254. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2024-2030 (USD MILLION)
  • TABLE 255. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 256. SOUTH KOREA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 257. TAIWAN DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 258. TAIWAN DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 259. TAIWAN DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2023 (USD MILLION)
  • TABLE 260. TAIWAN DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2024-2030 (USD MILLION)
  • TABLE 261. TAIWAN DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 262. TAIWAN DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 263. TAIWAN DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 264. TAIWAN DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 265. TAIWAN DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2023 (USD MILLION)
  • TABLE 266. TAIWAN DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2024-2030 (USD MILLION)
  • TABLE 267. TAIWAN DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 268. TAIWAN DRAVET SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 269. THAILAND DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 270. THAILAND DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 271. THAILAND DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2023 (USD MILLION)
  • TABLE 272. THAILAND DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2024-2030 (USD MILLION)
  • TABLE 273. THAILAND DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 274. THAILAND DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 275. THAILAND DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 276. THAILAND DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 277. THAILAND DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2023 (USD MILLION)
  • TABLE 278. THAILAND DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2024-2030 (USD MILLION)
  • TABLE 279. THAILAND DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 280. THAILAND DRAVET SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 281. VIETNAM DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 282. VIETNAM DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 283. VIETNAM DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2023 (USD MILLION)
  • TABLE 284. VIETNAM DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2024-2030 (USD MILLION)
  • TABLE 285. VIETNAM DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 286. VIETNAM DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 287. VIETNAM DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 288. VIETNAM DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 289. VIETNAM DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2023 (USD MILLION)
  • TABLE 290. VIETNAM DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2024-2030 (USD MILLION)
  • TABLE 291. VIETNAM DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 292. VIETNAM DRAVET SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 293. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 294. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 295. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2023 (USD MILLION)
  • TABLE 296. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2024-2030 (USD MILLION)
  • TABLE 297. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 298. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 299. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 300. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 301. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2023 (USD MILLION)
  • TABLE 302. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2024-2030 (USD MILLION)
  • TABLE 303. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 304. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 305. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 306. EUROPE, MIDDLE EAST & AFRICA DRAVET SYNDROME MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 307. DENMARK DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 308. DENMARK DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 309. DENMARK DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2023 (USD MILLION)
  • TABLE 310. DENMARK DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2024-2030 (USD MILLION)
  • TABLE 311. DENMARK DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 312. DENMARK DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 313. DENMARK DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 314. DENMARK DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 315. DENMARK DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2023 (USD MILLION)
  • TABLE 316. DENMARK DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2024-2030 (USD MILLION)
  • TABLE 317. DENMARK DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 318. DENMARK DRAVET SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 319. EGYPT DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 320. EGYPT DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 321. EGYPT DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2023 (USD MILLION)
  • TABLE 322. EGYPT DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2024-2030 (USD MILLION)
  • TABLE 323. EGYPT DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 324. EGYPT DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 325. EGYPT DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 326. EGYPT DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 327. EGYPT DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2023 (USD MILLION)
  • TABLE 328. EGYPT DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2024-2030 (USD MILLION)
  • TABLE 329. EGYPT DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 330. EGYPT DRAVET SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 331. FINLAND DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 332. FINLAND DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 333. FINLAND DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2023 (USD MILLION)
  • TABLE 334. FINLAND DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2024-2030 (USD MILLION)
  • TABLE 335. FINLAND DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 336. FINLAND DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 337. FINLAND DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 338. FINLAND DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 339. FINLAND DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2023 (USD MILLION)
  • TABLE 340. FINLAND DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2024-2030 (USD MILLION)
  • TABLE 341. FINLAND DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 342. FINLAND DRAVET SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 343. FRANCE DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 344. FRANCE DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 345. FRANCE DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2023 (USD MILLION)
  • TABLE 346. FRANCE DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2024-2030 (USD MILLION)
  • TABLE 347. FRANCE DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2018-2023 (USD MILLION)
  • TABLE 348. FRANCE DRAVET SYNDROME MARKET SIZE, BY MEDICATIONS, 2024-2030 (USD MILLION)
  • TABLE 349. FRANCE DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2018-2023 (USD MILLION)
  • TABLE 350. FRANCE DRAVET SYNDROME MARKET SIZE, BY SEIZURE TYPE, 2024-2030 (USD MILLION)
  • TABLE 351. FRANCE DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2018-2023 (USD MILLION)
  • TABLE 352. FRANCE DRAVET SYNDROME MARKET SIZE, BY SEVERITY, 2024-2030 (USD MILLION)
  • TABLE 353. FRANCE DRAVET SYNDROME MARKET SIZE, BY END-USE, 2018-2023 (USD MILLION)
  • TABLE 354. FRANCE DRAVET SYNDROME MARKET SIZE, BY END-USE, 2024-2030 (USD MILLION)
  • TABLE 355. GERMANY DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2018-2023 (USD MILLION)
  • TABLE 356. GERMANY DRAVET SYNDROME MARKET SIZE, BY OFFERING, 2024-2030 (USD MILLION)
  • TABLE 357. GERMANY DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2018-2023 (USD MILLION)
  • TABLE 358. GERMANY DRAVET SYNDROME MARKET SIZE, BY DIAGNOSIS & TESTING SOLUTIONS, 2024-2030 (USD MILLION)

TABL